Skip to main content
IMS Events Main banner
Rate ePoster

    Treatment of Newly Diagnosed Myeloma (excluding t-cell redirection therapy)

    Category: Treatment of Newly Diagnosed Myeloma (excluding t-cell redirection therapy)

    Survival Impact of Anti-CD38-Based Quadruplet Regimens in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: A Network Meta-Analysis and Reconstructed Individual Patient Data Meta-Analysis

    (PA-435) Survival Impact of Anti-CD38-Based Quadruplet Regimens in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: A Network Meta-Analysis and Reconstructed Individual Patient Data Meta-Analysis

    Friday, September 19, 2025
    Has Audio
    Introduction: Frontline therapy for transplant-ineligible newly diagnosed multiple myeloma (TI-NDMM) has evolved significantly. Although triplet regimens have long constituted the standard of care, recent quadruplet combinations incorporating anti-CD38 monoclonal antibodies (mAb), daratumumab and isatuximab, have demonstrated improved response rates and progression-free survival (PFS). However, the impact on long-term outcomes, particularly overall survival (OS), remains uncertain.

    Methods: We conducted a systematic review, network meta-analysis (NMA), and reconstructed individual patient data meta-analysis to evaluate survival outcomes of quadruplet versus triplet lenalidomide-containing regimens in TI-NDMM. This study adhered to Cochrane and PRISMA guidelines and was registered on PROSPERO (CRD420251033401). A comprehensive literature search through April 2025 identified randomized clinical trials (RCT) evaluating quadruplet and triplet regimens involving daratumumab, isatuximab, bortezomib, lenalidomide, and dexamethasone in any combination, compared to their backbone regimens, reporting OS and PFS. The NMA employed a frequentist random-effects model with P-scores for treatment ranking. Individual patient data were reconstructed from published Kaplan-Meier curves using the IPDfromKM method to enable pooled survival analyses.

    Results: Four RCT (CEPHEUS, IMROZ, MAIA, SWOG S0777) comprising 2,038 patients were included: D-VRd (n=197), I-VRd (n=265), D-Rd (n=368), VRd (n=614), and Rd (n=598). Median follow-up ranged from 58.7 to 89.3 months. Estimated 60-month PFS rates were: D-VRd (66.4%), I-VRd (63.3%), D-Rd (51.9%), and VRd (42.6%). Both D-VRd and I-VRd significantly improved PFS vs. D-Rd (HR 0.65, 95% CI 0.48–0.87, P=0.003; and HR 0.68, 95% CI 0.52–0.89, P=0.004) and vs. VRd (HR 0.51, 95% CI 0.39–0.67, P< 0.0001; and HR 0.53, 95% CI 0.41–0.67, P< 0.0001). D-Rd also showed superior PFS over VRd (HR 0.77, 95% CI 0.64–0.93; P=0.007). At 60 months, OS rates were: D-VRd (72.8%), I-VRd (72.2%), D-Rd (67.1%), and VRd (66.2%). When analyzed as grouped strategies, quadruplets (D-VRd, I-VRd) achieved significantly superior outcomes at 60 months compared with triplets (D-Rd, VRd), with higher PFS (64.7% vs. 46.3%) and OS (72.5% vs. 66.7%). Pooled analysis confirmed improved PFS (HR 0.57, 95% CI 0.47–0.69, P< 0.0001) and OS (HR 0.78, 95% CI 0.63–0.96, P=0.02) for quadruplets. The OS benefit of quadruplets was consistent in comparisons against both D-Rd (HR 0.77; 95% CI: 0.60–0.98; P=0.04) and VRd (HR 0.77; 95% CI: 0.62–0.97; P=0.02). In the NMA, D-VRd and I-VRd ranked highest in probability of achieving complete response or better (P-scores: 0.9876 and 0.7318), PFS (0.8668 and 0.8114), and OS (0.7043 and 0.8328).

    Conclusions: This meta-analysis provides the first comprehensive comparative assessment of anti-CD38-mAb based quadruplet versus triplet regimens in TI-NDMM, demonstrating a significant overall survival advantage and supporting quadruplet regimens as the most effective frontline treatment.